38 citations
,
March 2015 in “Journal of controlled release” IMSG nanoparticles improve vaccine delivery and immune response through hair follicles.
6 citations
,
October 2024 in “Journal of Family Medicine and Primary Care” Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.
21 citations
,
November 2015 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” There is no cure for alopecia areata, but treatments like JAK inhibitors show promise.
September 2024 in “Journal of the American Academy of Dermatology” AH-001 could be a safer and more effective treatment for hair loss.
1 citations
,
August 2022 in “Journal of Drugs in Dermatology” More frequent PRP sessions with shorter intervals improve hair loss treatment.
30 citations
,
August 2015 in “JAAD case reports” Platelet-rich plasma (PRP) injections successfully treated a woman's steroid-resistant hair loss, causing hair to regrow within a month.
41 citations
,
February 2021 in “Cureus” Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.
June 2020 in “Dermatologic therapy” Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
April 2015 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Farudodstat may effectively treat alopecia areata by protecting hair follicles without harmful effects.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
March 2025 in “Journal of Clinical Medicine” Iron chelators can effectively reduce hair loss and improve hair growth in autoimmune alopecia.
December 1989 in “Inpharma (Balgowlah)” Cyproterone helps women with hair loss caused by genetics. More research is needed to confirm the best dose.
January 2024 in “Clinical and Experimental Dermatology” Baricitinib helps treat severe hair loss in people over 65.
15 citations
,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
November 2003 in “Journal of Neurochemistry” Allopregnanolone may enhance alcohol's effects on dopamine neurons, influencing addiction risk.
January 2026 in “Journal of Clinical Medicine” Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.
September 2022 in “Frontiers in Immunology” Anti-androgen therapy may boost immunity but increases injection site pain in vaccinated patients.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
8 citations
,
September 2021 in “EMBO Molecular Medicine” A new small peptide may help hair growth by activating a specific receptor and should be tested in humans.
April 2018 in “Journal of Investigative Dermatology” Blocking α-toxin helps heal Staphylococcus aureus-infected wounds faster in both normal and diabetic mice, with different effects on their immune responses.
August 2023 in “Journal of analytical & pharmaceutical research” Microneedle-assisted therapy with human basic fibroblast growth factor significantly regrew hair in patients with hair loss.
2 citations
,
September 2019 in “Neurology Neuroimmunology & Neuroinflammation” IVIg treatment improved symptoms but caused permanent dark hair loss.
Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
9 citations
,
September 2019 in “Journal of Cosmetic Dermatology” PRP injections improve hair density in male hair loss.
April 2019 in “Journal of Investigative Dermatology” Blocking LFA-1 prevents hair loss in mice.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
July 2004 in “Current Urology Reports”
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.